Nivolumab

SAN FRANCISCO — Healio spoke with Moshe Ornstein, MD, about the COSMIC-313 trial presented at the annual ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — In this video, Moshe Ornstein, MD, highlights findings from the follow-up data of the CheckMate 9ER trial presented at the annual ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — Moshe Ornstein, MD, spoke with Healio about a trial of intermittent therapy in patients with metastatic renal cell carcinoma presented at the annual ASCO Genitourinary Cancers Symposium.

In this edition, nivolumab confers durable survival benefit; global economic cost of cancer estimated to exceed $25 trillion; phase 3 trials of pembrolizumab miss primary endpoints, and more.

SAN FRANCISCO — In this video, Toni K. Choueiri, MD, highlights a biomarker analysis of CheckMate 9ER he presented at the annual ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — Healio spoke with Toni K. Choueiri, MD, about follow-up data from the CheckMate 9ER presented at ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — In this video, Toni K. Choueiri, MD, who was the senior author, discusses an analysis of COSMIC-313 presented at ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — In this video, Meredith M. Regan, ScD, discusses a study she presented at the annual ASCO Genitourinary Cancers Symposium that assessed treatment-free survival outcomes among patients with advanced clear cell renal cell carcinoma.

SAN FRANCISCO — Nivolumab plus cabozantinib extended OS and PFS compared with sunitinib as first-line treatment for patients with advanced renal cell carcinoma, according to updated results of the randomized phase 3 CheckMate 9ER trial.

SAN FRANCISCO — Adjuvant nivolumab improved outcomes compared with placebo for patients with high-risk muscle-invasive urothelial carcinoma, according to study results.